
Florence Apparailly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8024744/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	New insights into macrophage heterogeneity in rheumatoid arthritis. Joint Bone Spine, 2021, 88, 105091.	1.6	13
2	TNFR1-d2 carrying the p.(Thr79Met) pathogenic variant is a potential novel actor of TNFα/TNFR1 signalling regulation in the pathophysiology of TRAPS. Scientific Reports, 2021, 11, 4172.	3.3	1
3	â€~SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models. Annals of the Rheumatic Diseases, 2021, 80, 714-726.	0.9	51
4	Novel insights into macrophage diversity in rheumatoid arthritis synovium. Autoimmunity Reviews, 2021, 20, 102758.	5.8	76
5	Synovial macrophages: from ordinary eaters to extraordinary multitaskers. Trends in Immunology, 2021, 42, 368-371.	6.8	17
6	POLR1B and neural crest cell anomalies in Treacher Collins syndrome type 4. Genetics in Medicine, 2020, 22, 547-556.	2.4	63
7	PSMB10, the last immunoproteasome gene missing for PRAAS. Journal of Allergy and Clinical Immunology, 2020, 145, 1015-1017.e6.	2.9	42
8	Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis. Frontiers in Immunology, 2020, 11, 1716.	4.8	13
9	Dysregulation of microRNA expression in the skin during cutaneous adverse drug reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3279-3283.	5.7	2
10	Dissecting the phenotypic and functional heterogeneity of mouse inflammatory osteoclasts by the expression of Cx3cr1. ELife, 2020, 9, .	6.0	38
11	LARP7 variants and further delineation of the Alazami syndrome phenotypic spectrum among primordial dwarfisms: 2 sisters. European Journal of Medical Genetics, 2019, 62, 161-166.	1.3	14
12	MicroRNAs: Fine Tuners of Monocyte Heterogeneity. Frontiers in Immunology, 2019, 10, 2145.	4.8	23
13	Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions. Frontiers in Immunology, 2019, 10, 1408.	4.8	137
14	MicroRNAs in juvenile idiopathic arthritis: Can we learn more about pathophysiological mechanisms?. Autoimmunity Reviews, 2019, 18, 796-804.	5.8	9
15	MicroRNAs: Key Regulators to Understand Osteoclast Differentiation?. Frontiers in Immunology, 2019, 10, 375.	4.8	41
16	Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis. Cells, 2019, 8, 1521.	4.1	18
17	Arthritis sensory and motor scale: predicting functional deficits from the clinical score in collagen-induced arthritis. Arthritis Research and Therapy, 2019, 21, 264.	3.5	7
18	Beneficial Effect of Alcohol Withdrawal on Gut Permeability and Microbial Translocation in Patients with Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2018, 42, 32-40.	2.4	29

#	Article	IF	CITATIONS
19	Delivery of miR-146a to Ly6C ^{high} Monocytes Inhibits Pathogenic Bone Erosion in Inflammatory Arthritis. Theranostics, 2018, 8, 5972-5985.	10.0	64
20	Advanced microRNA-based cancer diagnostics using amplified time-gated FRET. Chemical Science, 2018, 9, 8046-8055.	7.4	32
21	miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study. Haematologica, 2017, 102, 746-754.	3.5	22
22	A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (<i>NLRP1-</i> associated autoinflammation with arthritis and dyskeratosis). Annals of the Rheumatic Diseases, 2017, 76, 1191-1198.	0.9	181
23	Breaking Prometheus's curse for cartilage regeneration. Nature Reviews Rheumatology, 2017, 13, 516-518.	8.0	2
24	07.16â€Nlrp1 mutations cause autoinflammatory diseases in human: implication of the nlrp1 inflammasome?. , 2017, , .		0
25	CRISPR-Cas9: A revolution in genome editing in rheumatic diseases. Joint Bone Spine, 2017, 84, 1-4.	1.6	4
26	microRNA target prediction programs predict many false positives. Genome Research, 2017, 27, 234-245.	5.5	219
27	<i>TMEM187-IRAK1</i> Polymorphisms Associated with Rheumatoid Arthritis Susceptibility in Tunisian and French Female Populations: Influence of Geographic Origin. Journal of Immunology Research, 2017, 2017, 1-12.	2.2	9
28	X-Linked miRNAs Associated with Gender Differences in Rheumatoid Arthritis. International Journal of Molecular Sciences, 2016, 17, 1852.	4.1	55
29	Effects of alcohol withdrawal on monocyte subset defects in chronic alcohol users. Journal of Leukocyte Biology, 2016, 100, 1191-1199.	3.3	21
30	Deregulation and therapeutic potential of microRNAs in arthritic diseases. Nature Reviews Rheumatology, 2016, 12, 211-220.	8.0	118
31	Inhibition of Inflammation and Bone Erosion by RNA Interference–Mediated Silencing of Heterogeneous Nuclear RNP A2/B1 in Two Experimental Models of Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2536-2546.	5.6	21
32	MicroRNA Profiling of B Cell Subsets from Systemic Lupus Erythematosus Patients Reveals Promising Novel Biomarkers. International Journal of Molecular Sciences, 2015, 16, 16953-16965.	4.1	33
33	Transcriptomic Network Support Distinct Roles of Classical and Non-Classical Monocytes in Human. International Reviews of Immunology, 2014, 33, 470-489.	3.3	45
34	Circulating miRNA-125b ls a Potential Biomarker Predicting Response to Rituximab in Rheumatoid Arthritis. Mediators of Inflammation, 2014, 2014, 1-9.	3.0	83
35	High efficiency cell-specific targeting of cytokine activity. Nature Communications, 2014, 5, 3016.	12.8	62
36	Targeting monocytes/macrophages in the treatment of rheumatoid arthritis. Rheumatology, 2013, 52, 590-598.	1.9	185

#	Article	IF	CITATIONS
37	siRNA-based therapeutic approaches for rheumatic diseases. Nature Reviews Rheumatology, 2013, 9, 56-62.	8.0	43
38	Nicotinamide phosphoribosyltransferase/visfatin expression by inflammatory monocytes mediates arthritis pathogenesis. Annals of the Rheumatic Diseases, 2013, 72, 1717-1724.	0.9	38
39	Impact of microRNAs on the understanding and treatment of rheumatoid arthritis. Current Opinion in Rheumatology, 2013, 25, 225-233.	4.3	55
40	Persistent Luminescence Nanoparticles for Bioimaging. Advances in Intelligent and Soft Computing, 2012, , 37-53.	0.2	4
41	RNAi-mediated gene silencing in inflammatory monocytes for efficient immuno-intervention in experimental arthritis. Annals of the Rheumatic Diseases, 2012, 71, A75.1-A75.	0.9	0
42	PLGA microspheres encapsulating siRNA anti-TNFalpha: Efficient RNAi-mediated treatment of arthritic joints. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 457-464.	4.3	35
43	What do microRNAs mean for rheumatoid arthritis?. Arthritis and Rheumatism, 2012, 64, 11-20.	6.7	63
44	Gene Therapy for Rheumatoid Arthritis. BioDrugs, 2011, 25, 381-391.	4.6	15
45	E2F transcription factor-1 regulates oxidative metabolism. Nature Cell Biology, 2011, 13, 1146-1152.	10.3	222
46	Animal models for arthritis: innovative tools for prevention and treatment. Annals of the Rheumatic Diseases, 2011, 70, 1357-1362.	0.9	92
47	MicroRNAs as new player in rheumatoid arthritis. Joint Bone Spine, 2011, 78, 17-22.	1.6	39
48	Cytosolic phospholipase A2α gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis and Rheumatism, 2011, 63, 681-690.	6.7	25
49	Therapeutic mesenchymal stem or stromal cells in rheumatic diseases: rationale, clinical data and perspectives. Clinical Investigation, 2011, 1, 1269-1277.	0.0	2
50	miRNAs and rheumatoid arthritis - promising novel biomarkers. Swiss Medical Weekly, 2011, 141, w13175.	1.6	22
51	In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood, 2010, 116, 3505-3516.	1.4	57
52	Prospects for gene therapy in inflammatory arthritis. Best Practice and Research in Clinical Rheumatology, 2010, 24, 541-552.	3.3	15
53	Looking for microRNA polymorphisms as new rheumatoid arthritis risk loci?. Joint Bone Spine, 2010, 77, 377-379.	1.6	9
54	Adenoâ€associated virus type 5–mediated intraarticular administration of tumor necrosis factor small interfering RNA improves collagenâ€induced arthritis. Arthritis and Rheumatism, 2010, 62, 765-770.	6.7	30

#	Article	IF	CITATIONS
55	Glucocorticoidâ€induced leucine zipper is an endogenous antiinflammatory mediator in arthritis. Arthritis and Rheumatism, 2010, 62, 2651-2661.	6.7	80
56	Quantitative imaging of cartilage and bone for functional assessment of gene therapy approaches in experimental arthritis. Journal of Tissue Engineering and Regenerative Medicine, 2010, 4, 387-394.	2.7	8
57	Adeno-Associated Virus–Mediated IL-10 Gene Transfer Suppresses Lacrimal Gland Immunopathology in a Rabbit Model of Autoimmune Dacryoadenitis. , 2010, 51, 5137.		19
58	From Stem Cells to Bone: Phenotype Acquisition, Stabilization, and Tissue Engineering in Animal Models. ILAR Journal, 2010, 51, 42-61.	1.8	36
59	Gene therapy for arthritis. , 2010, , 1-18.		Ο
60	Cationic liposome formulations for RNAi-based validation of therapeutic targets in rheumatoid arthritis. Current Opinion in Molecular Therapeutics, 2010, 12, 325-30.	2.8	6
61	miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice. PLoS ONE, 2009, 4, e7542.	2.5	172
62	Concerted stimuli regulating osteo-chondral differentiation from stem cells: phenotype acquisition regulated by microRNAs. Acta Pharmacologica Sinica, 2009, 30, 1369-1384.	6.1	35
63	RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opinion on Biological Therapy, 2009, 9, 535-538.	3.1	32
64	Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes. Arthritis and Rheumatism, 2008, 58, 2356-2367.	6.7	95
65	Antitumoral Activity and Osteogenic Potential of Mesenchymal Stem Cells Expressing the Urokinase-Type Plasminogen Antagonist Amino-Terminal Fragment in a Murine Model of Osteolytic Tumor. Stem Cells, 2008, 26, 2981-2990.	3.2	40
66	Transient down-regulation of cbfa1/Runx2 by RNA interference in murine C3H10T1/2 mesenchymal stromal cells delays in vitro and in vivo osteogenesis, but does not overtly affect chondrogenesis. Experimental Cell Research, 2008, 314, 1495-1506.	2.6	28
67	Immunomodulatory Dendritic Cells Inhibit Th1 Responses and Arthritis via Different Mechanisms. Journal of Immunology, 2007, 179, 1506-1515.	0.8	86
68	Micro-CT combined with bioluminescence imaging: A dynamic approach to detect early tumor–bone interaction in a tumor osteolysis murine model. Bone, 2007, 40, 1032-1040.	2.9	46
69	Microenvironmental changes during differentiation of mesenchymal stem cells towards chondrocytes. Arthritis Research and Therapy, 2007, 9, R33.	3.5	149
70	Mesenchymal Stem Cells Inhibit the Differentiation of Dendritic Cells Through an Interleukin-6-Dependent Mechanism. Stem Cells, 2007, 25, 2025-2032.	3.2	562
71	RNAi in arthritis: prospects of a future antisense therapy in inflammation. Current Opinion in Molecular Therapeutics, 2007, 9, 483-9.	2.8	6
72	Earlier Onset of Syngeneic Tumors in the Presence of Mesenchymal Stem Cells. Transplantation, 2006, 82, 1060-1066.	1.0	122

#	Article	IF	CITATIONS
73	Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor α in experimental arthritis. Arthritis and Rheumatism, 2006, 54, 1867-1877.	6.7	175
74	Immature Dendritic Cells Suppress Collagen-Induced Arthritis by In Vivo Expansion of CD49b+ Regulatory T Cells. Journal of Immunology, 2006, 177, 3806-3813.	0.8	94
75	87. Efficient Delivery of Small Interfering RNA Targeting Pro_Inflammatory Cytokines in Experimental Arthritis. Molecular Therapy, 2006, 13, S36.	8.2	Ο
76	1067. Amelioration of Arthritis after Local Delivery of an Adeno-Associated Virus Type 6 Expressing a TNF-Blocking Agent under a Disease-Inducible Promoter. Molecular Therapy, 2006, 13, S409.	8.2	0
77	Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor α in collagenâ€induced arthritis. Arthritis and Rheumatism, 2005, 52, 1595-1603.	6.7	344
78	Tetracycline-Inducible Viral Interleukin-10 Intraocular Gene Transfer, Using Adeno-Associated Virus in Experimental Autoimmune Uveoretinitis. Human Gene Therapy, 2005, 16, 1037-1046.	2.7	49
79	Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Research and Therapy, 2005, 7, R1304.	3.5	178
80	Gene Therapy Platform for Bone Regeneration Using an Exogenously Regulated, AAV-2-Based Gene Expression System. Molecular Therapy, 2004, 9, 587-595.	8.2	114
81	Short-Term BMP-2 Expression Is Sufficient for In Vivo Osteochondral Differentiation of Mesenchymal Stem Cells. Stem Cells, 2004, 22, 74-85.	3.2	212
82	Antigen-specific immunomodulation of collagen-induced arthritis with tumor necrosis factor-stimulated dendritic cells. Arthritis and Rheumatism, 2004, 50, 3354-3364.	6.7	63
83	Mesenchymal stem cells and rheumatoid arthritis. Joint Bone Spine, 2003, 70, 483-485.	1.6	24
84	Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 2003, 102, 3837-3844.	1.4	1,079
85	Tetracycline Transcriptional Silencer Tightly Controls Transgene Expression AfterIn VivoIntramuscular Electrotransfer: Application to Interleukin 10 Therapy in Experimental Arthritis. Human Gene Therapy, 2002, 13, 2161-2172.	2.7	67
86	Tetracycline-Inducible Interleukin-10 Gene Transfer Mediated by an Adeno-Associated Virus: Application to Experimental Arthritis. Human Gene Therapy, 2002, 13, 1179-1188.	2.7	84
87	Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis and Rheumatism, 2001, 44, 1444-1454.	6.7	47
88	Immunological evaluation of cytokine and anticytokine immunotherapy in vivo: what have we learnt?. Annals of the Rheumatic Diseases, 1999, 58, 136-141.	0.9	16
89	Systemic viral interleukin-10 gene delivery prevents cartilage invasion by human rheumatoid synovial tissue engrafted in SCID mice. Arthritis and Rheumatism, 1999, 42, 678-685.	6.7	37
90	Role of sialic acid residues in the in vitro superactivity of human choriogonadotropin (hCG) in rat Leydig cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1994, 1224, 559-565.	4.1	9